Want to see HK:3681 full AI Analyst Report?
SinoMab Bioscience Ltd. (3681) AI Stock Analysis
Top Page
SinoMab Bioscience Ltd.
(HKEX:3681)
Weak financial performance from revenue collapse and ongoing losses is the dominant factor; neutral technical signals and standard biotech valuation provide only modest offset.
SinoMab Bioscience Ltd. (3681) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.48B
- Dividend Yield
- ―
- Average Volume (3M)
- 756.43K
- Price to Earnings (P/E)
- -6.9
- Beta (1Y)
- 1.00
- Revenue Growth
- ―
- EPS Growth
- -4.24%
- Country
- Hong Kong
- Employees
- 73
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
SinoMab Bioscience Ltd. Business Overview & Revenue Model
Company Description
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly in...
How the Company Makes Money
SinoMab Bioscience primarily makes money through (1) commercialization of any approved products (e.g., sales of antibody therapeutics) and (2) out-licensing and partnering arrangements for its drug candidates, which can generate upfront payments, dev...
SinoMab Bioscience Ltd. Financial Statement Overview
Summary
Revenue collapsed to zero in 2025 with persistent net losses, though losses narrowed and equity rebounded; cash burn improving but sustainability concerns remain high.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 2.03M | 1.36M | 4.03M | 26.66M |
| Gross Profit | 0 | -26.64M | 543.00K | 422.00K | 4.03M | 26.66M |
| EBITDA | -125.75M | -72.11M | -132.89M | -200.46M | -230.89M | -285.20M |
| Net Income | -181.77M | -102.27M | -185.14M | -243.11M | -284.16M | -288.19M |
Balance Sheet | ||||||
| Total Assets | 684.46M | 908.50M | 753.10M | 847.79M | 1.01B | 1.04B |
| Cash, Cash Equivalents and Short-Term Investments | 226.21M | 382.40M | 106.88M | 234.66M | 376.19M | 589.53M |
| Total Debt | 266.78M | 338.64M | 482.27M | 450.81M | 357.18M | 275.46M |
| Total Liabilities | 323.00M | 400.41M | 560.19M | 552.20M | 498.77M | 361.43M |
| Stockholders Equity | 361.45M | 508.10M | 192.91M | 295.58M | 509.57M | 680.23M |
Cash Flow | ||||||
| Free Cash Flow | -112.79M | -95.78M | -172.30M | -237.74M | -413.29M | -345.30M |
| Operating Cash Flow | -80.23M | -70.48M | -130.80M | -133.85M | -300.54M | -147.06M |
| Investing Cash Flow | -99.30M | 16.25M | -94.48M | -96.92M | -81.36M | -137.70M |
| Financing Cash Flow | 218.96M | 329.39M | 73.27M | 82.27M | 102.28M | 57.52M |
SinoMab Bioscience Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3681, the sentiment is Neutral. The current price of 1.07 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.09, and below the 200-day MA of 1.37, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 48.97 is Neutral, neither overbought nor oversold. The STOCH value of 34.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3681.
SinoMab Bioscience Ltd. Peers Comparison
Overall Rating
HK:699870Outperform
HK:231569Neutral
HK:269664.6Neutral
HK:218157Neutral
HK:996652Neutral- HK:368144Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6998 | 70Outperform | HKD 3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% |
| HK:2315 | 69Neutral | HKD 17.02B | 38.23 | 15.94% | ― | 48.04% | 166.72% |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:2181 | 57Neutral | HKD 1.79B | 17.80 | 48.25% | ― | 88.38% | ― |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:3681 | 44Neutral | HKD 1.47B | -6.85 | -41.81% | ― | ― | -4.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3681 | SinoMab Bioscience Ltd. | 1.07 | -0.70 | -39.55% | |
| HK:6998 | Genor Biopharma Holdings Limited | 1.62 | -1.51 | -48.24% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:2315 | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H | 38.30 | 9.06 | 30.98% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
SinoMab Bioscience Ltd. Corporate Events
SinoMab Clarifies Use of 2025 Share Proceeds and Share Award Details
SinoMab BioScience has issued a supplemental announcement to its 2025 Annual Report, clarifying how it deployed funds raised from two share subscription exercises completed in May and July 2025 under a general mandate. The company confirmed that the...
SinoMab Shareholders Unanimously Back Disposal Deal at Extraordinary Meeting
Shareholders of SinoMab BioScience Limited have overwhelmingly approved a key disposal transaction at an extraordinary general meeting held on 7 September 2026 in Hong Kong. The ordinary resolution to confirm, approve and ratify the sale and purchase...
SinoMab Advances Antibody Pipeline With New Trials and Preclinical Milestones
SinoMab BioScience reported interim results for the six months to 30 June 2026, highlighting major progress across its monoclonal antibody pipeline for immune and inflammatory disorders. The board noted that all condensed interim financial statements...
SinoMab Seeks Shareholder Approval to Sell Suzhou Industrial Property for RMB280 Million
SinoMab BioScience Limited has called an extraordinary general meeting in Hong Kong on 7 September 2026 for shareholders to vote on a proposed disposal of industrial property in Suzhou. The assets involved comprise state-owned construction land use r...
SinoMab Schedules Board Meeting to Approve 2026 Interim Results
SinoMab BioScience Limited has scheduled a board meeting for 31 August 2026 to review and approve its interim results for the six months ended 30 June 2026. The meeting will also cover related matters and the subsequent publication of the half-year f...
SinoMab Sets September EGM on Major Suzhou Facility Disposal
SinoMab BioScience Limited, a Hong Kong–incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, develops and manufactures antibody‑based therapies and operates research and production facilities in mainland China, i...
SinoMab BioScience COO and Executive Director Steps Down
SinoMab BioScience announced that executive director and chief operating officer Fang Liang has resigned from all positions within the group, effective 18 August 2026, to pursue personal endeavours. The board stated that Liang has no disagreements wi...
SinoMab BioScience Clarifies Board and Committee Roles in Governance Update
SinoMab BioScience Limited has announced the current composition of its board of directors, led by Executive Director Dr. Shui On Leung, who serves as both chairman and chief executive officer, alongside several non-executive and independent non-exec...
SinoMab Delays Dispatch of Circular on Major Suzhou Asset Disposal
SinoMab BioScience has announced a further delay in sending a shareholder circular related to its planned disposal of a Suzhou property and facility, a transaction classified as a major deal under Hong Kong listing rules. The circular, which will pro...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 01, 2026